KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Non-inferiority in cancer clinical trials was associated with more lenient margins and higher hypothesized outcome event rates.

Yazhou He, Chi Shu, Ting Li, Qingbin Wu, Ziqiang Wang, Xin Chen, Xia Shen

J Clin Epidemiol 139 214-221

PMID34437946
PMCID-
DOI10.1016/j.jclinepi.2021.08.020
发表日期2021-08-26
摘要

摘要

OBJECTIVE: To identify potential bias in non-inferiority design of published cancer trials, and to provide suggestions for future practice. STUDY DESIGN AND SETTING: We systematically searched MEDLINE, Embase and CENTRAL databases (until April 17, 2020) to obtain non-inferiority phase III cancer trials and protocols. Distribution of essential characteristics and study design parameters was compared between trials with and without concluding non-inferiority using multivariable logistic regression. RESULTS: A total of 291 eligible trials were included. We observed that increased odds of concluding non-inferiority was significantly associated with more lenient non-inferiority margins (OR = 1•94, 95% CI 1•02-3•69) and higher hypothesized event rate (OR = 1•24, 95% CI 1•06-1•47). Trials that established non-inferiority adopted margins that were more dispersedly distributed (dispersion OR = 2•90, 95% CI 1•88-4.48). CONCLUSION: Although limited by the exploratory nature, our study demonstrated existence of possible distorted non-inferiority design which could incur excess non-inferiority in cancer clinical trials. Pre-registration and transparent reporting of detailed non-inferiority design is imperative for future research.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。